LifeMD, Inc. LFMD
Regular-session close
After hours · Nov 20, 7:37 PM ET
- YTD
- -57.62%
- 1 year
- -61.05%
5D -0.07 (-3.95%)
- Market cap
- 69.84M
- Revenue (ttm)
- 193.06M
- Profit margin
- -11.66%
- EPS (ttm)
- -0.49
- Shares out
- 43.31M
- Forward P/E
- -124.75
- YTD return
- -57.62%
- 1-year return
- -61.05%
- 50-day average
- 5.34
- Volume
- 1.58M
- Avg volume
- 911.04K
- Open
- 1.57
- Previous close
- 1.60
- Day's range
- 1.38 – 1.58
- 52-week range
- 1.38 – 5.38
- Beta
- 1.23
- Analysts
- Strong Buy
- Price target
- 12.00 (+730.4%)
Key statistics
- 200-day average
- 7.01
- Enterprise value
- 207.61M
- Price / sales
- 1.12
- Revenue growth
- 38.30%
- Free cash flow
- 18.01M
- Total cash
- 37.59M
- Total debt
- 25.14M
- Short % of float
- 16.08%
Fundamental scorecard
7 of 25 checks passed on LFMD’s reported financials
7of 25 checks passed
- Value 1 of 5
- Growth 3 of 5
- Profitability 1 of 5
- Financial health 2 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.10 | -0.14 | -0.04 | -40.00% |
| Aug 7, 2024 | Jun 1, 2024 | -0.13 | -0.19 | -0.06 | -46.15% |
| May 8, 2024 | Mar 1, 2024 | -0.13 | -0.19 | -0.06 | -46.15% |
| Mar 11, 2024 | Dec 1, 2023 | -0.14 | -0.12 | +0.02 | +14.29% |
| Nov 8, 2023 | Sep 1, 2023 | -0.18 | -0.20 | -0.02 | -11.11% |
| Aug 9, 2023 | Jun 1, 2023 | -0.09 | -0.23 | -0.14 | -155.56% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 10, 2024 | Lake Street | init | — | Buy |
| Dec 4, 2024 | Mizuho | init | — | Neutral |
| Nov 11, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 20, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Aug 20, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Aug 9, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
About LifeMD, Inc.
LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies. It also provides LifeMD PC, a direct-to-consumer virtual primary care which includes 24/7 access to a provider for their primary care, urgent care, and chronic care needs; and offers virtual consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, and more. In addition, the company offers PDFSimpli, an online software as a service platform that allows users to create, edit, convert, sign, and share PDF documents; ResumeBuild which provides digital resume and cover letter services; SignSimpli, a digital signature platform; and LegalSimpli, a provider of legal forms for consumers and small businesses. It sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was incorporated in 1994 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Health Information Services
- Country
- United States
- Website
- lifemd.com
News
HC Wainwright & Co. Maintains Buy on LifeMD, Lowers Price Target to $6
LifeMD: 3 Key Takeaways for Long-Term Investors Lake Street Maintains Buy on LifeMD, Lowers Price Target to $3
12 Health Care Stocks Moving In Friday's Intraday Session Mizuho Maintains Outperform on LifeMD, Lowers Price Target to $6
12 Health Care Stocks Moving In Friday's Pre-Market Session
LifeMD, Inc. (LFMD) Q3 2026 Earnings Call Transcript LifeMD Q3 EPS $(0.11) Beats $(0.14) Estimate, Sales $44.625M Miss $48.885M Estimate
LifeMD Lowers FY2026 Sales Guidance from $205.500M-$212.500M to $188.000M-$191.000M vs $207.582M Est
LifeMD Announces Agreement For Its Pharmacies To Directly Dispense, Ship Eli Lilly's Self-Pay GLP-1 Medicines
Your note
Sign in to keep a note on LFMD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALVAREZ NICHOLAS P | Officer | Stock Award(Grant) | Mar 20, 2024 | 405,000 |
| DITROLIO JOSEPH | Director | Stock Award(Grant) | Dec 5, 2024 | 251,048 |
| GALLUPPI STEFAN | Officer | Purchase | Sep 10, 2024 | 45,449 |
| JINDAL PIYUSH | Director | Stock Award(Grant) | Jul 16, 2024 | 362,335 |
| MACRAE CALUM ARCHIBALD | Director | Stock Award(Grant) | Apr 25, 2024 | 16,500 |
| SCHREIBER JUSTIN | Chief Executive Officer | Sale | Dec 1, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 5.73% | 2,481,761 | 12.38M | Sep 29, 2024 |
| Vanguard Group Inc | 3.93% | 1,702,566 | 8.50M | Sep 29, 2024 |
| Divisadero Street Capital Management, LP | 3.48% | 1,508,403 | 7.53M | Sep 29, 2024 |
| State Street Corporation | 2.67% | 1,155,495 | 5.77M | Sep 29, 2024 |
| Royce & Associates LP | 2.08% | 901,041 | 4.50M | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.89% | 819,233 | 4.09M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.15% | 932,528 | 4.65M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.04% | 882,948 | 4.41M | Oct 30, 2024 |
| Royce Small-Cap Opportunity Fund | 1.20% | 517,878 | 2.58M | Sep 29, 2024 |
| SPDR (R) Ser Tr-SPDR� Kensho New Economies Composite ETF | 1.14% | 492,787 | 2.46M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.04% | 449,945 | 2.25M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.83% | 357,871 | 1.79M | Aug 30, 2024 |
